Nanocurcumin (6C & 30C) on incidence of ILI & COVID-19 type respiratory illness

Effectiveness of Nanocurcumin (6C & 30C) on incidence of Influenza-like illness & COVID-19 type respiratory illness in urban slum dwellers Ã¢â?¬â?? A Longitudinal study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/035906

Enrollment

17000

Registered

2021-08-24

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nanocurcumin-6C: Dose for children below 5 years: 2 pills of medicine Nanocurcumin 6C once in every week for first 2 months, followed by once in 2 weeks. Ã¢â?¬Â¢ Dose for individuals 5

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy individuals living in the same community 2. Written Informed consent by head of the family 3. No symptom of Influenza like illness/COVID-19 at the time of enrolment.

Exclusion criteria

Exclusion criteria: 1. Individuals with symptoms of Influenza like illness/ COVID-19 in last 14 days 2. Pregnant women and lactating mother 3. Child below age of 1 year. 4. Individuals taking other homoeopathic medicines for prevention of Influenza like illness/COVID-19 5. Patients with malignancy, immunocompromised state, life threatening diseases, end stage diseases.

Design outcomes

Primary

Measure	Time frame
Incidence of Influenza-like illness & COVID-19 type respiratory illness.Timepoint: Weekly till completion of 1 year.	—

Secondary

Measure	Time frame
1. Changes/severity of symptoms. 2. Prevalence of other acute diseases. 3. Time to recovery. 4. Need of hospitalization.Timepoint: Weekly till completion of 1 year.	—

Countries

India

Contacts

Public ContactDr Debadatta Nayak

CCRH

drdnayak@gmail.com09873404012

Outcome results